Get the Latest News from Senior Executives at DCAT Week ’16
By

What are the major company developments impacting the pharmaceutical manufacturing value chain? DCAT’s Member Company Announcement Forum kicks off DCAT Week ’16 with the latest news and insight from senior executives.

The DCAT Member Company Announcement Forum, a new event for DCAT Week ’16, will provide a front row seat to learn of the important strategy developments, mergers and acquisitions (M&A), integration efforts, and key expansion activity from leading executives whose companies are making the news. It will be held on Monday, March 14, 2016 from 10:00 AM to 12:30 PM in the Peacock Alley Room, Waldorf Astoria (located behind the restaurant/bar on the main level in the hotel). This event is complimentary and open to all members company representatives (no registration is required). 

Some highlights from presenting companies include:

 

  • Pfizer. Pfizer’s $17-billion acquisition of Hospira in 2015 was a key move for Pfizer in building its product portfolios in sterile injectables and biosimilars, but it also added to the company’s manufacturing network, including the combined company’s contract manufacturing activities. Gain the latest insight on the integration of Pfizer and Hospira, including its contract manufacturing activities

 

 

  • Boehringer Ingelheim. Boehringer Ingelheim announced plans earlier this year to invest approximately EUR 500 million ($537 million) in biopharmaceutical production at its site in Vienna, Austria, through the addition of a new large-scale biopharmaceutical production facility for active ingredients manufactured using cell cultures. Learn of the expansion and how it fits in the company’s manufacturing and supply network.

 

 

  • MilliporeSigma. Merck KGaA’s $17-billion acquisition of Sigma-Aldrich was one of largest deals among suppliers in 2015 and was the largest in the history of Merck KGaA. The deal was the key piece of a multiyear strategy for Merck KGaA in transforming itself from a pharma and chemicals company into a science and technology company with three businesses in healthcare, life sciences, and performance materials. Key for 2016 will be integration of the two companies, including the combined life science businesses. Gain insight into this integration and the life sciences offering of the combined company.

 

 

  • Saltigo. Saltigo, a custom manufacturer of fine chemicals for the pharmaceutical and agrochemical industries and part of Lanxess, is investing approximately EUR 60 million ($65 million) to expand the production facilities of Saltigo in Leverkusen, Germany. The investment represents the single largest investment in Saltigo since it was founded as a fine chemicals company in 2006. Gain further insight on the rationale for the expansion and how fits into the company’s overall manufacturing and supply network.

 

 

  • Siegfried AG. In 2015, Siegfried AG completed its acquisition of three former BASF sites in Evionnaz, Switzerland, Saint-Vulbas, France, and Minden, Germany, to add to its manufacturing and supply capabilities for active pharmaceutical ingredients and intermediates. This acquisition was a key step in Siegfried’s strategy, which included previous acquisitions of California-based AMP and Hameln Pharma and a new production plant in Nantong, China. Learn how these moves fit into the company’s overall strategy and of other company developments.

 

These highlights are only a portion of what is in store for the DCAT Member Company Announcement Forum. Other participating companies include: AMRI, Patheon, Helm, CMC Biologics, IDT Biologika, Infa, CordenPharma, STA Pharmaceutical Co., Ltd., A WuXi AppTec Company, Novasep, and J-STAR Research.

The schedule of speakers may be found here.

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

The CDMO/CMO Report: Cell and Gene Therapies
By

By
Although a niche market, cell and gene therapy development and manufacturing continues to be an active area of investment by CDMOs/CMOs. Facing limited industry capacity, both pure-play CDMOs and bio/pharma companies with CDMO services continue to expand. A roundup of the latest expansions.

Pharma Innovation: AI in Drug Manufacturing
By

By
What is the potential of artificial intelligence (AI) in pharmaceutical manufacturing and what regulatory considerations come into play, including between CDMOs/CMOs and sponsor companies? The FDA has issued a discussion paper to highlight key issues and is seeking input from the industry.

Pharma Industry Outlook: What Lies Ahead?
By

By
With 2023 well underway, the crucial question is: how will the bio/pharmaceutical industry perform in 2023 and the near term? The DCAT Week program, Pharma Industry Outlook, will provide key market data and trends. Plus, a pharma financial outlook and analysis of M&A, partnering deals, and private and public financing into Emerging Pharma. 

ROI in Pharma R&D Falls in Post-Pandemic Market
By

By
A recent analysis by the management consultancy firm, Deloitte, shows that the bio/pharma industry’s return on investment (ROI) in R&D has fallen in the post-pandemic market. Projected ROI in pharma R&D in 2022 fell to 1.2%, the lowest ROI observed in the 13 years since the firm has conducted the study.